Priced at $17, raising $289 million

Attovia raised $289 million, one of the largest biotech raises in a year of scarce deals. Morgan Stanley, Leerink, Citigroup and RBC ran the books, giving the multispecific antibody developer a fully funded shot at public markets.

Attovia sets $289 million IPO size ahead of Nasdaq debut

Attovia's second S-1 amendment locks in a 17 million share deal sized at $289 million, one of the larger biotech listings to reach this stage this year. Morgan Stanley, Leerink, Citigroup, RBC and LifeSci are running the book, so pricing is the next milestone to watch.

Attovia Therapeutics filed for a Nasdaq IPO with Morgan Stanley and Citigroup co-leading the offering as biotech's 2026 recovery builds momentum.